Urinary tract infections (UTIs) are common in women, and become more frequent during menopause. Getting a UTI doesn’t just ruin a weekend. UTI’s aren’t just an innocuous bladder infection. They can lead to more dangerous infections. Left unchecked, or if improperly treated, UTIs can lead to kidney infections, hospital stays, and, in vulnerable people, even sepsis—a life‑threatening, whole‑body infection that can become deadly. In this health tip I will explain the role of 17-beta estradiol and probiotics in vaginal and urinary health and the importance of embracing both of these non-antibiotic options as a standard and powerful step in preventing both vaginal and urinary bladder infections that can lead to serious complications and even systemic sepsis.
Sepsis ranks among the top causes of hospital deaths in the United States—frequently described as the leading or second cause.
According to the CDC, at least 1.7 million U.S. adults develop sepsis each year, and at least 350,000 die during hospitalization or are discharged to hospice. Critically, 1 in 3 adults who dies in a hospital had sepsis during that stay.
In the U.S., urinary tract infections (UTIs) rank among the top primary infection sites for sepsis—typically first or second overall. In a large U.S. nationwide study (using NIS data on millions of sepsis hospitalizations), urinary tract infections were the leading site at 36.7%, essentially tied with lower respiratory tract infections at 36.6%, followed by systemic fungal infections (~9%).
For women leading up to and after menopause or in other low‑estrogen states, a critical piece of the puzzle is hiding in plain sight: low vaginal estrogen, in particularly menopausal loss of 17-beta estradiol, the primary pre- menopausal estrogen responsible for keeping the vagina at a healthy acidic pH of 3.8 to 4.5. The decline in estradiol at menopause (or with other hypoestrogenic states) is a significant risk factor for recurrent UTIs and, if not treated adequately, progression to urosepsis. Doctors don’t explain to women that estradiol supports glycogen production in the vaginal epithelium. Then lactobacilli metabolize that glycogen into lactic acid, maintaining the protective acidic vaginal pH. With estradiol loss, glycogen production falls, the “good” lactobacilli begin to die, and vaginal pH rises toward alkaline. Tissue lining the vagina and urinary system gets thinner and more fragile with loss of estradiol.
This shift in vaginal pH from acidic (low pH) toward alkaline (higher pH) favors colonization by pathological urinary and vaginal bacteria (commonly E. coli from stool), which increases susceptibility to both vaginal infections and ascending UTIs. This mechanism is central to the genitourinary syndrome of menopause (GSM).
Restoring healthy vaginal pH using vaginal estradiol can dramatically cut rates of both urinary and vaginal infections, and reduce the risk of serious complications, such as kidney infections and even more serious sepsis. Local topical vaginal estradiol therapy is an evidence-based therapy for restoring the acidic environment, promoting lactobacilli, and substantially reducing recurrent UTI rates, often by 50% or more in studies.
Vaginal estradiol (which can be in the form of a generic Rx cream, vaginal ring, or vaginal tablet) is a common sense, low cost, non-antibiotic prophylaxis approach that will not only reduce UTIs but also help prevent sepsis and help keep women out of the hospital.
Tragically for women, many clinicians are either unaware of this estrogen connection in UTIs or they refuse to consider vaginal estradiol Rx due to erroneous beliefs held over from the earlier, misleading FDA black box warnings the makers of Premarin and Prempro lobbied to have applied to all estrogen products after their products were implicated in the 2001 Women’s Health Initiative risks. This black box warning never should have applied to all estrogen products, especially low dose vaginal estrogen. Women have suffered for the last 25 years from being denied proper estrogen therapy. The Trump Administration FDA Commissioner in 2025 finally removed this black box warning from the FDA required labeling, but many doctors, nurse practitioners, and PAs treating women still do not know that.
There is further good news. After 25 years of misinformation, under the leadership of HHS Secretary RFK, Jr and new FDA and NIH leadership, there have been major efforts made to undo the damage from the flawed reports from the WHI. Medicine in the U.S. is finally, slowly catching up to what has been known since the 1980s and studies I included in my 1995 book Screaming to be Heard – Hormone Connections Women Suspect and Doctors Ignore (2001 revised and updated edition available on Amazon in hardback and Kindle).
The American Urology Association (AUA) also finally in 2025 updated their guidelines from the last publication in 2019 to now say that women in perimenopause and postmenopausal who struggle with recurrent UTIs should be given vaginal estradiol to reduce the risk of further urinary tract infections.
Why estrogen matters to decrease UTI risk
In women’s reproductive years, estrogen—primarily the active form of 17-beta estradiol (E2)—quietly maintains a powerful defense system in the vagina and lower urinary tract. Estrone (E1) is the “reservoir” form of estrogen mainly in body fat, while estriol (E3) is a placental estrogen during pregnancy, but isn’t as potent to maintain vaginal tissue health.
Estradiol has several key functions to maintain urogenital health:
- E2 keeps the vaginal and urethral lining thick, moist, and resilient, creating a physical barrier that makes it harder for bacteria to penetrate the mucosal linings (vagina and ureter) and then ascend upward into the bladder to cause inflammation, pain and infection.
- E2 supports glycogen production that feeds the lactobacillus bacteria to maintain a healthy microbiome dominated by lactobacilli, the “good” bacteria that produce lactic acid and keep vaginal pH low. Acidic pH is a hostile environment to the common bacteria that cause UTI, such as Escherichia coli. Note: alkaline semen ejaculated into the vagina during sex is one reason many women with declining estradiol in perimenopause describe having more UTIs after sex!
- E2 helps maintain local immune defenses—the immune cells and antimicrobial factors that quickly neutralize invaders before they become full‑blown infections.
When estrogen falls—as it does with onset of menses each month, after delivery of a baby, after surgical menopause, in natural perimenopause and post menopause, or with certain hormone‑lowering therapies—these normal vaginal and urinary defenses are seriously weakened: vaginal lining gets thinner, drier, more fragile and prone to tears, pH rises, lactobacilli die off, and more aggressive, infection-causing bacteria now have a favorable environment to grow. In a nutshell, this is the reason UTIs occur more frequently in women whose vaginal estrogen levels are low.
Younger women on high progestin (or progestin-only) contraceptives also have suppressed overall estrogen and lower vaginal estrogen, making them also more susceptible to UTIs and more serious infections for all the reasons I outlined above.
How common are UTIs and why this matters
UTIs are the most common bacterial infection in women. About 50–60% of women will experience at least one UTI in their lifetime, and roughly a quarter of those will have recurrent infections. Recurrent UTI is typically defined as two infections in six months or three in a year. The number of women with recurrent UTIs are rising in those who have gotten the COVID injections because the spike protein and LNPs in the mRNA shots damage ovarian hormone production and also interfere with normal immune system regulation.
Beyond discomfort, recurrent UTIs can create a cascade of problems:
- Women are given repeated courses of antibiotics, which drive antibiotic resistance, and kill “good” bacteria in the gut, vaginal and urinary systems, seriously disrupting the healthy balance of microorganisms needed for defense against infections.
- Increased risk of ascending infection (kidney involvement) and systemic bacteremia as invading bacteria enter the blood stream. This last complication is especially common and serious in older or medically complex patients.
- In hospitalized patients with chronic kidney disease, 10–15% of UTI patients progress to urosepsis (sepsis from a urinary source), one of the most common causes of sepsis. Onset of sepsis significantly increases risk of death.
BOTTOM LINE: UTIs are not always “simple.” For women with underlying risk factors, reducing the number and severity of urinary infections can become a matter of life and death—not just treating a nuisance problem.
Genitourinary Syndrome of Menopause: Another Related and Common Problem
As women enter perimenopause and menopause, estradiol levels drop, and a cluster of symptoms called genitourinary syndrome of menopause (GSM) increases dramatically, becoming a significant problem for up to 84% of postmenopausal women.
Symptoms include vaginal dryness, burning, itching, pain with intercourse, urinary urgency and frequency.
These medical problems are not just “annoying,” as women are often told. These physiological changes after loss of estradiol directly increase UTI risk, and in turn increase risk of more serious infections:
- Thinner, more fragile vaginal and urethral epithelium is easier to tear, and these tears in the lining allow bacteria to penetrate and colonize.
- Vaginal pH rises and lactobacilli decline, allowing colonization by gram‑negative bacilli like E. coli and Klebsiella.
- Pelvic floor weakening increases incontinence and, sometimes, prolapse—both independently linked to higher UTI rates.
Clinical studies show that postmenopausal women are disproportionately affected by recurrent and complicated UTIs, compared with younger women. So, when you add comorbidities like diabetes, chronic kidney disease, or heart failure, the likelihood that a UTI will escalate into full-blown sepsis increases even further. Genitourinary Syndrome of Menopause is not just about comfort; it’s a risk state for recurrent infection and more serious systemic infections.
Vaginal estradiol: the many ways it reduces risk of infections
Vaginal estradiol delivers a small dose of estrogen directly to the vaginal tissues, with minimal systemic absorption, especially at low doses. The goal is not to “raise hormones everywhere,” but to repair and restore the health of the local tissues in the vagina. Vaginal estradiol works to:
- thicken and re‑vascularizes the vaginal and urethral epithelium, which restores these protective barriers.
- lower vaginal pH to acidic levels, which allows lactobacilli to repopulate, which then crowds out UTI‑causing bacteria that don’t thrive in acidic environments.
- improve local immune responses in the urinary and vaginal tracts, helping your body contain infections early.
Clinical data supports these effects of vaginal estradiol::
- A multicenter retrospective review of more than 5,600 women with low estradiol levels and recurrent UTIs found that after starting vaginal estrogen, their average UTIs dropped from 3.9 per year to 1.8—a 51.9% reduction. For women dealing with the pain of UTIs, that’s a huge reduction and helps improve quality of life as well as reducing the risk of more serious infections.
- Over half of the women in this study had one or fewer UTIs in the following year, and nearly a third had none at all.
- Randomized trials using contemporary vaginal estradiol regimens show significantly fewer UTIs in treated women compared with placebo.
- Mechanistic studies show that topical estrogen restores lactobacilli and normalizes urinary inflammatory markers, which links changes in the microorganisms to lower infection risk.
BOTTOM LINE: Vaginal estradiol used regularly leads to fewer UTIs which means fewer antibiotics, fewer kidney infections, and a lower chance of sepsis in high‑risk women.
Review of Current AUA Guidelines: Major urology societies have updated their guidance for women based on this overwhelming evidence:
The AUA/SUFU/AUGS Genitourinary Syndrome of Menopause Guideline (2025) states that for women with GSM and recurrent UTIs, clinicians should recommend low‑dose vaginal estrogen to reduce future infections, assuming no contraindications and using shared decision‑making. The updated guideline lists vaginal estrogen as a non‑antibiotic preventive strategy for peri‑ and postmenopausal women, along with options like cranberry and methenamine.
These recommendations refer broadly to “local low‑dose vaginal estrogen”—in the United States in practice, the most common and most reliable forms of estrogen are the commercially-available, prescription FDA‑approved estradiol vaginal tablets (Vagifem and generics), vaginal ring (Estring), or low‑dose estradiol creams (Estrace brand and several generics), which have robust safety and absorption data.
NOTE on COST AND AVAILABILITY: These vaginal estradiol products I listed above are available in the US at low cost in local pharmacies, and are typically covered by medical insurance plans. These estradiol products are also available with your physician’s Rx through TheHRTClub.com at steep discounted cash pay direct to consumer prices.
You do not need the more expensive compounded products advertised by “hormone doctors” and compounding pharmacies (who like to sell their own formulas because they have much higher markups and profits than possible with FDA-approved commercially available E2 options.
BOTTOM LINE: This is an important shift: major specialty societies now consider vaginal estrogen standard of care for recurrent UTI prevention in women with low estrogen. It should be your first step, not a last‑ditch approach!
Try our GSM and UTI Assessment Tool!
Click here to access our patient education self-test tool from Truth for Health Foundation — developed by Elizabeth Lee Vliet, M.D. and Kathy Kresnik to assist you with self-screening that helps identify signs consistent with Genitourinary Syndrome of Menopause (GSM). Our tool follows the criteria defined by the AUA/SUFU/AUGS as symptoms and tissue changes from declining estrogen and androgen in the genitourinary tract during the menopause transition. Our tool helps identify your risk factors for recurrent urinary tract infections (UTIs) and helps you start a constructive conversation with your health care professional about use of vaginal estrogen to alleviate symptoms and reduce risk of infections.
This report references the 2025 AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause (J Urol. 2025;214(3):242-250) and the 2025 AUA/CUA/SUFU update on Recurrent Uncomplicated UTIs in Women (J Urol. 2026;215(1):3-12). Recurrent UTI is defined as ≥2 episodes in 6 months or ≥3 episodes in 12 months. Both guidelines emphasize shared decision-making — treatment choice should reflect your goals, preferences, and risk profile, discussed with a licensed clinician.
This tool is provided by Truth for Health Foundation, a 501(c)(3) public charity as an educational service to help you talk with your personal physician(s). It is not medical advice. Our tool is a screening aid, not a diagnostic device. It does not prescribe medication and does not replace an in-person evaluation, pelvic exam, or urinalysis/culture where clinically indicated.
Who should consider vaginal estradiol?
Over the 40 years of my medical practice specializing on the overlooked hormone connections from puberty to late life in women and men, I have used combinations of vaginal estradiol with systemic hormone treatment for the whole range symptoms women experience as a result of hormone imbalances, whatever the cause. I have found that systemic hormone therapy alone doesn’t always prevent vaginal and urinary symptoms – we need the topical effects locally on the vaginal and urinary tissues. I describe my approaches in more detail in my books, especially Screaming to be Heard – Hormone Connections Women Suspect and Doctors Ignore (2001 revised and updated edition available on Amazon in hardback and Kindle), especially the chapter on Estrogen and the Bladder.
I don’t see vaginal and urinary symptoms as something to only be treated with topical estrogen if BOTH are present, as the AUA 2025 guideline suggests. Either problem alone responds to local estradiol therapy, if done consistently at the right dose, with the right product for each woman, and for the right duration of time. Some women use vaginal estradiol options for years, with excellent results to prevent UTIs, urinary leakage, and pain with intercourse due to dryness. So with this background in mind based on my many years of actual clinical experience treating thousands of women, let’s look at what the guidelines say (clearly, more rigid than what I actually do in practice to help individual patients based on their needs).
- Perimenopausal and postmenopausal women with GSM and recurrent UTIs
- At least 2 UTIs in 6 months or 3 in a year.
- GSM symptoms: vaginal dryness, burning, pain with intercourse, urinary urgency/frequency.
- Often not on systemic hormone therapy, or on regimens that don’t adequately address local GSM (Dr. Vliet note: this is VERY common. We don’t fully understand why adequate systemic estrogen therapy doesn’t consistently relieve GMS symptoms).
- Women with induced or surgical hypoestrogenism (low estrogen levels)
- Surgical menopause (either hysterectomy with oophorectomy OR hysterectomy alone, since blood flow to the ovaries is reduced by more than 50% when the uterine artery is tied off to remove the uterus, and that loss of blood flow means ovaries decline more rapidly to menopausal endocrine production levels).
- Certain breast cancer or gynecologic cancer therapies that dramatically lower estrogen (e.g., aromatase inhibitors, GnRH agonists). These women often experience amplified GSM and recurrent UTIs. Current data shows that the ultra-low doses of vaginal estradiol products are considered safe for breast cancer patients.
- High‑risk women where each UTI carries extra danger: reducing the number of urinary infections is not just about comfort; it is about reducing hospitalizations and sepsis risk.
- Presence of other medical conditions: chronic kidney disease, diabetes, heart failure, or indwelling catheters.
- Older age with frailty or limited mobility, difficulty maintaining adequate hygiene in the urogenital area.
Safety: what the data actually show
It is a national tragedy that more doctors are still operating in fear about “estrogen” from the flawed WHI study that hit the news in 2002, with exaggerated headlines about risk (since disproven) and ignored benefits. This problem requires more background than I can go into in this short Health Tip. So I am focused here solely on safety data using the low‑dose vaginal estradiol options.
- Systemic absorption is minimal at approved low vaginal doses; blood estradiol levels often remain unchanged from baseline low postmenopausal levels prior to using vaginal estradiol.
- Large reviews have not found increases in cardiovascular events or stroke from low‑dose vaginal estrogen used for GSM or UTI prevention.
- For women with a history of breast cancer, more current data and guideline statements support individualized use of ultra‑low‑dose vaginal estrogen, especially when GSM and recurrent UTIs severely impact quality of life and also may affect adherence to cancer therapy.
This doesn’t mean “no risk” in every case, and women need individualized assessments and discussion of risks. But overall, the risk profile of vaginal estradiol is minimal and in many women, the benefits clearly outweigh the risks.
What this means for doctors—and for women
For decades, the reflex UTI strategy has been “treat with antibiotics, repeat as needed.” That approach ignores the root cause of low estradiol in millions of women with genital and urinary tissues. The newer evidence and guidelines tell a different story: vaginal estradiol is a core component of effective prevention and treatment. To our readers, if your doctor has closed the book on hormone therapy because of a 24-year old flawed study and has not read anything on it since 2002, it is time to look for a new doctor!
In summary, we know (and have known for several decades) that vaginal estradiol cuts UTI rates by half or more in women with low estrogen and recurrent infections. It addresses the underlying vulnerability—thin tissue, disrupted microbiome, weak local immunity—rather than just killing bacteria after they’ve already invaded. It can reduce antibiotic exposure, resistance, and the risk of dangerous complications like pyelonephritis and urosepsis, especially in older or comorbid women.
Given all that I have shared with you in this Health Tip, it is time for doctors to:
- Stop treating recurrent UTIs in hypoestrogenic women as “bad luck” or purely behavioral issues.
- Routinely ask about GSM symptoms and hormone status when UTIs recur.
- Offer low‑dose vaginal estradiol as a first‑line non‑antibiotic preventive option, in line with AUA guidance, instead of relying solely on repeated antibiotics.
- Explain to patients that repeated use of antibiotics have far more adverse effects and health risks due to disruption of the entire microbiome of the body!
- Engage in careful, evidence‑based conversations about benefits and risks with women who have more complex histories (e.g., breast cancer survivors), rather than avoiding vaginal estrogen by default.
BOTTOM LINE: For women, the practical message is straightforward:
If you’re having multiple UTIs a year, and you’re also noticing vaginal dryness, pain with sex, or urinary urgency, there is a good chance that low local estrogen is part of the problem. Ask your clinician specifically about low‑dose vaginal estradiol for prevention, not just “more antibiotics.” Bring up the newer urology guidelines and your infection history. You’re not being difficult—you’re advocating for a solution that treats the root cause! Don’t be passive and silent when it comes to your health!
How Do I Restore the Vaginal and Gut Microbiome After Antibiotics for UTIs?
There are several ways to restore the healthy bacterial balance in the vagina, and for the gut as well if you had to take a systemic antibiotic to treat a UTI. First of all, I encourage you to read my earlier Health Tips on the unique features of our high-quality multi-species, multi-strain probiotics, available here: https://www.truthforhealth.org/2024/04/health-tip-from-dr-vliet-featuring-truprobiotic-complex/
https://www.truthforhealth.org/2024/03/health-tip-from-dr-vliet/
After a course of systemic antibiotics, you really should consider taking a two week course of a high volume, multi-strain probiotic. Then change to a daily probiotic with a variety of foods that are fermented and provide prebiotic fiber. These steps will help tremendously. For myself, my family and my patients, I recommend the TruProbiotic Complex followed by the TruProbiotic Daily to replenish bifidobacteria and other needed species.
You may also want to consider the synergistic benefit with a vaginal probiotic option to further support vaginal microbial balance.
One tool I recommend to patients navigating this is V-Probiotics by Vitanica, a vaginal suppository containing five targeted Lactobacillus strains (including L. crispatus, L. gasseri, and L. jensenii, L. reuteri, and L. rhamnosus) that are naturally dominant in a healthy vaginal microbiome.
Research shows that women whose vaginal flora is rich in these specific species have lower rates of vaginal dryness, atrophy, and irritation (Journals of Gerontology), and multiple clinical trials have found that restoring vaginal Lactobacillus — particularly L. crispatus — meaningfully reduces recurrent UTI episodes in women prone to them, including postmenopausal women (Clinical Infectious Diseases; Frontiers in Microbiology).
This new product we added to our Truth for Health Store is specifically formulated to help restore the protective vaginal balance that reduces risk of another vaginal bacterial infection or UTI.
Combining vaginal estradiol with a Lactobacillus-based vaginal probiotic like V-Probiotics targets two complementary mechanisms of genitourinary syndrome of menopause (GSM) and recurrent UTI risk, and the evidence supports real synergy. Vaginal estradiol restores glycogen in the vaginal epithelium, which is the fuel Lactobacillus needs to recolonize and produce protective lactic acid. Multiple studies confirm topical vaginal estrogen reliably increases Lactobacillus abundance, lowers vaginal pH, and restores a healthier microbiome community — effects that are most pronounced in women who start out with a dysbiotic (Lactobacillus-poor) vaginal microbiome. Then adding a direct probiotic supplies the beneficial bacteria themselves rather than waiting for estrogen alone to recruit them, which can accelerate and reinforce recolonization.
V-Probiotics is a new product we have added to our store!
While there isn’t a clinical trial on this exact commercial blend, the strains it contains are well-studied and have an excellent safety record, with no serious side effects reported across the research. It’s a gentle, low-risk option that works well on its own or alongside vaginal estrogen for women looking for extra support with dryness, discomfort, or recurrent UTIs during this life stage. As always, check with your own personal health professional before starting any new supplement, especially if you’re pregnant or have a specific vaginal health concern that needs evaluation first.
As you put all the pieces together that I have described today, I encourage you to consider our other natural medicines with our top quality, cGMP-compliant professional formulas: TruMitochondrial™ Boost, TruNAC™, Tru BioD3, Tru B™ Complex Full Spectrum, TruZinc™, TruC with BioFlavonoids (Natural sourced Vitamin C with complete Bioflavonoids), and TruProBiotic™ Daily to replenish critical bifidobacteria depleted by COVID shots, viral illnesses, and antibiotic therapy.
All Truth for Health Foundation Products Meet or Exceed cGMP Quality Standards, the highest quality standard for supplements sold in the USA. For more information, references from studies are listed in the Product Data Sheets for each product, available on our website. Check us out at www.TruthforHealth.org Click on tab for Store. OR www.shopTruthforHealth.com
CAUTION: As always, we urge you to avoid supplements without checking knowledgeable sources to evaluate your medical situation, proper lab tests to verify what is needed, and to make sure to avoid adverse interactions with prescription medicines and other supplements you take. Under medical practice regulations, we are unable to answer individual medical questions or make specific individual supplement recommendations for people who are not established patients of Dr. Vliet’s independent medical practice (www.ViveLifeCenter.com).
To Your good health and improving resilience!
Elizabeth Lee Vliet, MD
